Polarean Imaging – IPO

Northland Capital Partners is pleased to announce that Polarean Imaging (POLX.L) has listed on AIM raising £3m. Polarean is a revenue generating, medical drug-device combination company operating in the high resolution medical imaging market. Net proceeds of the Placing are expected to be used for the Company’s Phase III clinical trials to gain clearance to market hyperpolarised Xenon gas (129Xe) as a contrast agent and the polariser as a device.